Should airway hyperresponsiveness be included in the definition of clinical remission with biologic therapy in severe asthma

Brian Lipworth; Chris RuiWen Kuo; Kirsten Stewart; Rory Chan

doi:10.1016/j.jaip.2023.12.013

Should airway hyperresponsiveness be included in the definition of clinical remission with biologic therapy in severe asthma

Brian Lipworth (Lead / Corresponding author)
, Chris RuiWen Kuo
, Kirsten Stewart
, Rory Chan

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

127 Downloads (Pure)

Abstract

Airway hyper-responsiveness (AHR) is a tenet of the persistent asthma phenotype along with reversible airway obstruction and type 2 (T2) inflammation. Indirect acting challenges such as mannitol are more closely related to the underlying T2 inflammatory process as compared with direct challenges. In this review article, we summarise the current literature and explore the future role of mannitol AHR in clinical remission with biologics.

Original language	English
Pages (from-to)	904-907
Number of pages	4
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	12
Issue number	4
Early online date	11 Dec 2023
DOIs	https://doi.org/10.1016/j.jaip.2023.12.013
Publication status	Published - Apr 2024

Keywords

asthma
airway hyperresponsiveness
biologic
remission
Remission
Airway hyper-responsiveness
Biologic
Asthma

ASJC Scopus subject areas

Immunology and Allergy

Access to Document

10.1016/j.jaip.2023.12.013Licence: CC BY-NC-ND

Final published versionFinal published version, 364 KBLicence: CC BY-NC-ND

Cite this

@article{4ce70f8626c148c5a24600a2f535a1f0,

title = "Should airway hyperresponsiveness be included in the definition of clinical remission with biologic therapy in severe asthma",

abstract = "Airway hyper-responsiveness (AHR) is a tenet of the persistent asthma phenotype along with reversible airway obstruction and type 2 (T2) inflammation. Indirect acting challenges such as mannitol are more closely related to the underlying T2 inflammatory process as compared with direct challenges. In this review article, we summarise the current literature and explore the future role of mannitol AHR in clinical remission with biologics.",

keywords = "asthma, airway hyperresponsiveness, biologic, remission, Remission, Airway hyper-responsiveness, Biologic, Asthma",

author = "Brian Lipworth and Kuo, \{Chris RuiWen\} and Kirsten Stewart and Rory Chan",

note = "Copyright: {\textcopyright} 2023 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma \& Immunology.",

year = "2024",

month = apr,

doi = "10.1016/j.jaip.2023.12.013",

language = "English",

volume = "12",

pages = "904--907",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

publisher = "American Academy of Allergy, Asthma and Immunology",

number = "4",

}

Should airway hyperresponsiveness be included in the definition of clinical remission with biologic therapy in severe asthma. / Lipworth, Brian (Lead / Corresponding author); Kuo, Chris RuiWen; Stewart, Kirsten et al.
In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 12, No. 4, 04.2024, p. 904-907.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Should airway hyperresponsiveness be included in the definition of clinical remission with biologic therapy in severe asthma

AU - Lipworth, Brian

AU - Kuo, Chris RuiWen

AU - Stewart, Kirsten

AU - Chan, Rory

PY - 2024/4

Y1 - 2024/4

N2 - Airway hyper-responsiveness (AHR) is a tenet of the persistent asthma phenotype along with reversible airway obstruction and type 2 (T2) inflammation. Indirect acting challenges such as mannitol are more closely related to the underlying T2 inflammatory process as compared with direct challenges. In this review article, we summarise the current literature and explore the future role of mannitol AHR in clinical remission with biologics.

AB - Airway hyper-responsiveness (AHR) is a tenet of the persistent asthma phenotype along with reversible airway obstruction and type 2 (T2) inflammation. Indirect acting challenges such as mannitol are more closely related to the underlying T2 inflammatory process as compared with direct challenges. In this review article, we summarise the current literature and explore the future role of mannitol AHR in clinical remission with biologics.

KW - asthma

KW - airway hyperresponsiveness

KW - biologic

KW - remission

KW - Remission

KW - Airway hyper-responsiveness

KW - Biologic

KW - Asthma

U2 - 10.1016/j.jaip.2023.12.013

DO - 10.1016/j.jaip.2023.12.013

M3 - Article

C2 - 38097177

SN - 2213-2198

VL - 12

SP - 904

EP - 907

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

IS - 4

ER -

Should airway hyperresponsiveness be included in the definition of clinical remission with biologic therapy in severe asthma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this